News
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
— si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed
— 75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear or almost clear skin
selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell mediated autoimmune diseases, today announced positive results from the first-in-human Phase 1b trial of its lead compound, si-544, in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3.